Antibody discovery specialist AbCellera Biologics Inc (Nasdaq:ABCL) has formed a strategic collaboration with RQ Bio, a developer of medicines based on broad-spectrum monoclonal antibodies, the two companies announced on Wednesday.
AbCellera and RQ Bio plan to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV).
By bringing together RQ Bio's expertise in infectious diseases and viral evolution with AbCellera's discovery engine for finding rare, highly potent antibodies, the partners hope to provide long-lasting infectious disease medicines to high-risk patients.
Under the terms of the agreement, RQ Bio has the right to develop and commercialise therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and regulatory milestone payments and royalties on net sales of products.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer